Spero Therapeutics (NASDAQ:SPRO) Upgraded at Wall Street Zen
by Sarita Garza · The Markets DailyWall Street Zen upgraded shares of Spero Therapeutics (NASDAQ:SPRO – Free Report) from a hold rating to a strong-buy rating in a research note released on Sunday morning.
Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Spero Therapeutics in a research report on Thursday, January 22nd. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Reduce”.
Get Our Latest Analysis on Spero Therapeutics
Spero Therapeutics Stock Up 4.5%
SPRO opened at $2.34 on Friday. Spero Therapeutics has a 12-month low of $0.51 and a 12-month high of $3.22. The business has a 50 day moving average of $2.35 and a 200-day moving average of $2.31. The stock has a market cap of $135.46 million, a price-to-earnings ratio of 19.50 and a beta of 1.45.
Spero Therapeutics (NASDAQ:SPRO – Get Free Report) last posted its earnings results on Thursday, March 26th. The company reported $0.53 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.73. Spero Therapeutics had a return on equity of 22.53% and a net margin of 12.83%.The business had revenue of $41.30 million for the quarter, compared to analyst estimates of $26.00 million. As a group, analysts expect that Spero Therapeutics will post -1.2 earnings per share for the current year.
Insider Transactions at Spero Therapeutics
In other Spero Therapeutics news, insider Esther Rajavelu sold 87,917 shares of the firm’s stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $2.36, for a total transaction of $207,484.12. Following the completion of the sale, the insider directly owned 1,012,091 shares in the company, valued at $2,388,534.76. This trade represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 5.50% of the stock is owned by company insiders.
Hedge Funds Weigh In On Spero Therapeutics
A number of large investors have recently made changes to their positions in the company. XTX Topco Ltd bought a new stake in Spero Therapeutics in the 2nd quarter valued at $100,000. Quadrature Capital Ltd bought a new position in Spero Therapeutics during the 2nd quarter worth $90,000. Invesco Ltd. bought a new position in Spero Therapeutics during the 2nd quarter worth $43,000. Stonepine Capital Management LLC acquired a new stake in shares of Spero Therapeutics during the second quarter worth $455,000. Finally, Assenagon Asset Management S.A. acquired a new stake in shares of Spero Therapeutics during the third quarter worth $70,000. Institutional investors own 25.60% of the company’s stock.
About Spero Therapeutics
Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.
The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.